Peregrine Pharmaceuticals traded at $7.19 this Tuesday April 9th, increasing $0.55 or 8.28 percent since the previous trading session. Looking back, over the last four weeks, Peregrine Pharmaceuticals gained 10.62 percent. Over the last 12 months, its price fell by 64.09 percent. Looking ahead, we forecast Peregrine Pharmaceuticals to be priced at 6.97 by the end of this quarter and at 6.36 in one year, according to Trading Economics global macro models projections and analysts expectations.
Avid Bioservices, Inc. is a contract development and manufacturing organization (CDMO). The Company is focused on development and Current Good Manufacturing Practices (CGMP) manufacturing of biopharmaceutical products derived from mammalian cell culture. The Company provides a range of process development, CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. The Company’s services include CGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory strategy, submission and support. The Company also provides process development activities, including cell line development and optimization, cell culture and feed optimization, analytical methods development and product characterization.